Skip to main content
Premium Trial:

Request an Annual Quote

Biodesix: Jean Franchi, Hany Massarany

Biodesix has appointed Jean Franchi and Hany Massarany to its board of directors. Franchi has more than 30 years of biotechnology and life science industry experience ranging from pre-commercial to global commercial biotech operations. Massarany has extensive experience in the global diagnostics industry, with expertise in molecular diagnostic testing.

Franchi currently serves as chief financial officer for Replimune Group, a biotechnology company developing oncolytic immuno-gene therapies. She has led operational and financial strategy at several companies in domestic and international markets of various stages and sizes, including 16 years at Genzyme. She holds a bachelor's degree in business administration from Hofstra University.

Massarany served as president and chief executive officer of GenMark Diagnostics from 2011 to 2020. Prior to joining GenMark, he held the role of president at Ventana Medical Systems and head of Roche Tissue Diagnostics. From 1999 to 2009 he was responsible for various global leadership positions with Ventana. He has also held executive management positions with Bayer Diagnostics and Chiron Diagnostics. Massarany earned a bachelor’s degree in microbiology and immunology from Monash University and an MBA from Melbourne University.

The Scan

NFTs for Genome Sharing

Nature News writes that non-fungible tokens could be a way for people to profit from sharing genomic data.

Wastewater Warning System

Time magazine writes that cities and college campuses are monitoring sewage for SARS-CoV-2, an approach officials hope lasts beyond COVID-19.

Networks to Boost Surveillance

Scientific American writes that new organizations and networks aim to improve the ability of developing countries to conduct SARS-CoV-2 genomic surveillance.

Genome Biology Papers on Gastric Cancer Epimutations, BUTTERFLY, GUNC Tool

In Genome Biology this week: recurrent epigenetic mutations in gastric cancer, correction tool for unique molecular identifier-based assays, and more.